Janssen GlobalVarmennettu tili

@JanssenGlobal

At Janssen, we never stop working toward a future where disease is a thing of the past. Channel run by Janssen Global Services LLC, NJ, USA.

Raritan, New Jersey
Liittynyt toukokuu 2014

Twiitit

Olet estänyt käyttäjän @JanssenGlobal

Haluatko varmasti nähdä nämä twiitit? Twiittien näyttäminen ei poista käyttäjän @JanssenGlobal estoa.

  1. Kiinnitetty twiitti
    21. lokak.

    JUST IN: U.S. FDA authorizes our for emergency use for adults ages 18+ at least two months post-first shot. The Janssen COVID-19 Vaccine has not been approved/licensed by FDA.

    Kumoa
  2. 9 minuuttia sitten

    At we are reiterating our commitment to reduce the burden of stigma & improve health outcomes for people living with chronic hepatitis B. The NEW report from the spotlights critical steps needed to help end discrimination.

    Kumoa
  3. 19 tuntia sitten

    We are excited to partner with to launch a toolkit dedicated to supporting caregivers throughout their care journeys, so they can be in a better position to care for their loved ones. Click to view the toolkit:

    Kumoa
  4. 22 tuntia sitten

    Every day, Janssen Oncology remains focused on building a by helping address some of the toughest health challenges people face, including researching ways to eliminate cancer. Learn more about our work in action:

    Kumoa
  5. 23 tuntia sitten

    We are proud to support in their efforts to recognize family caregivers and encourage them to celebrate the identities and passions that enrich their lives.

    Kumoa
  6. 24 tuntia sitten

    People living with chronic hepatitis B may hide their condition or not come forward for testing due to fear of rejection in the workplace. The NEW Stigma Report from the sheds light on discriminatory policies worldwide.

    Kumoa
  7. 19. marrask.

    The reality for patients worldwide: clinical trials aren’t just a nice-to-have, they’re a need-to-have. And clinical trials need people. If you live with an immunological condition and are seeking more equitable and inclusive research, learn more here:

    Kumoa
  8. 18. marrask.

    Today marks the start of World Antimicrobial Awareness Week (). Antimicrobial resistance is a global health crisis that, if left unaddressed, poses a substantial threat to humanity. At Janssen, we’re focused on efforts to infections through innovation.

    Kumoa
  9. 18. marrask.

    Thank you to all who joined us for . We discussed our plans for short- and long-term growth, therapeutic area innovations, and more.

    Kumoa
  10. 18. marrask.

    National Family Caregivers Month is an important time to recognize for their integral role in supporting loved ones with . We thank you today, and every day, for your commitment.

    Kumoa
  11. 18. marrask.

    This , have “More Talk” about risk factors for prostate cancer, such as a family history of the disease and race and/or ethnicity. Anyone at risk of developing prostate cancer should take “More Action” this , including getting screened.

    Kumoa
  12. 18. marrask.

    James List, Neil Davie, Bill Martin and David Lee discussing our therapeutic areas of focus with Vanessa Broadhurst and Scott White.

    Kumoa
  13. 18. marrask.

    Scott White discusses Janssen’s commitment to developing inventive medicines, therapies and vaccines to help address unmet need.

    Kumoa
  14. 18. marrask.

    Vanessa Broadhurst, James List and Najat Khan examine Janssen’s pioneering of breakthrough approaches in retina disease at this year’s Pharmaceutical Business Review.

    Kumoa
  15. uudelleentwiittasi
    18. marrask.

    ., Vice Chairman of the Executive Committee, , discusses the future of healthcare at .

    Kumoa
  16. uudelleentwiittasi
    18. marrask.

    Jennifer Taubert, EVP, Worldwide Chairman, Pharmaceuticals, , shares how ’s focus on transformational medicine is helping advance the next wave of innovation at .

    Kumoa
  17. uudelleentwiittasi
    18. marrask.

    Joe Wolk, Executive Vice President, Chief Financial Officer, , discusses the progress we've shared at .

    Kumoa
  18. 18. marrask.

    During a Q&A discussion, Vanessa Broadhurst outlined our plans to launch novel gene and cell therapies around the world.

    Kumoa
  19. 18. marrask.

    Vanessa Broadhurst and Scott White join Penny Heaton, Peter Lebowitz and James Merson in today’s therapeutic area Q&A panel. Moderated by Jen McIntyre.

    Kumoa
  20. 18. marrask.

    Teri Lawver speaks to the challenge of unlocking the full potential of an investigational medicine.

    Kumoa
  21. 18. marrask.

    Peter Lebowitz, Vanessa Broadhurst and Rich Tillyer at this year’s Pharmaceutical Business Review discussing advancements in lung cancer.

    Kumoa

Lataaminen näyttää kestävän hetken.

Twitter saattaa olla ruuhkautunut tai ongelma on muuten hetkellinen. Yritä uudelleen tai käy Twitterin tilasivulla saadaksesi lisätietoja.

    Saatat pitää myös

    ·